Efficacy of Vaccination Against HPV Infections To Prevent Cervical Cancer in France: Present Assessment and Pathways To Improve Vaccination Policies
Efficacy of Vaccination Against HPV Infections To Prevent Cervical Cancer in France: Present Assessment and Pathways To Improve Vaccination Policies
Efficacy of Vaccination Against HPV Infections To Prevent Cervical Cancer in France: Present Assessment and Pathways To Improve Vaccination Policies
Abstract
Background: Seventy percent of sexually active individuals will be infected with Human Papillomavirus (HPV) during their
lifetime. These infections are incriminated for almost all cervical cancers. In France, 3,068 new cases of cervical cancer and
1,067 deaths from cervical cancer occurred in 2005. Two vaccines against HPV infections are currently available and
vaccination policies aim to decrease the incidence of HPV infections and of cervical cancers. In France, vaccine coverage has
been reported to be low.
Methods: We developed a dynamic model for the heterosexual transmission of Human Papillomavirus types 16 and 18,
which are covered by available vaccines. A deterministic model was used with stratification on gender, age and sexual
behavior. Immunity obtained from vaccination was taken into account. The model was calibrated using French data of
cervical cancer incidence.
Results: In view of current vaccine coverage and screening, we expected a 32% and 83% reduction in the incidence of
cervical cancers due to HPV 16/18, after 20 years and 50 years of vaccine introduction respectively. Vaccine coverage and
screening rates were assumed to be constant. However, increasing vaccine coverage in women or vaccinating girls before
14 showed a better impact on cervical cancer incidence. On the other hand, performing vaccination in men improves the
effect on cervical cancer incidence only moderately, compared to strategies in females only.
Conclusion: While current vaccination policies may significantly decrease cervical cancer incidence, other supplementary
strategies in females could be considered in order to improve vaccination efficacy.
Citation: Ribassin-Majed L, Lounes R, Clemencon S (2012) Efficacy of Vaccination against HPV Infections to Prevent Cervical Cancer in France: Present Assessment
and Pathways to Improve Vaccination Policies. PLoS ONE 7(3): e32251. doi:10.1371/journal.pone.0032251
Editor: Paulo Lee Ho, Instituto Butantan, Brazil
Received November 10, 2011; Accepted January 25, 2012; Published March 12, 2012
Copyright: 2012 Ribassin-Majed et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: laureen.majed@parisdescartes.fr
for about 3,000 new cases per year [6] while a thousand deaths are
due to these cancers annually. Moreover, cervical cancers occur
frequently in young women [7].
Vaccination against HPV infections represents an effective way
to decrease cervical cancer incidence, particularly among young
women. Two prophylactic vaccines against HPV infections are
available in France and have been found to be highly effective in
women who have never been infected with HPV [8].
The permanent Vaccines Advisory Committees (Comite
technique des vaccinations and Conseil superieur dhygie`ne
publique de France) recommend vaccinating 14 years old
females. Moreover, a catch-up program has been offered to
women aged from 15 to 23. Females eligible for the catch-up
program either not have been sexually active yet or may report a
first sexual relationship that occurred in the year prior to
vaccination (Haute Autorite de Sante, HAS). A recent paper has
estimated vaccine coverage in France to be low: about 30% of girls
aged 14 had been vaccinated with three doses in 2007 and 2008
Introduction
Human Papillomavirus infection (HPV) is the most frequent
sexually transmitted disease. At least 70 per cent of sexually active
men and women are infected with HPV during their life span [1].
Eighty per cent of HPV infections cases are cleared in a few
months by the immune system without treatment but in the
remaining 20%, infection becomes persistent. One hundred types
of HPV have been identified: low risk types, which are responsible
for benign anogenital lesions, and high risk types, which can lead
to precancerous and cancerous lesions in the cervix. HPV-16 is the
most common genotype in developed countries [2,3].
Epidemiological studies have established a causal relationship
between HPV infections and occurrence of cervical cancer [4].
These infections have also been incriminated in anogenital, head
and neck cancers, anogenital warts and recurrent respiratory
papillomatosis among women and men.
Invasive cervical cancer is the second most common cancer
among women worldwide [5]. In France, cervical cancer accounts
PLoS ONE | www.plosone.org
Methods
Dynamic Model Structure
We used Scilab-5.1.1 software (http://www.scilab.org/fr) to
design a deterministic model for heterosexual transmission of HPV
types 16 and 18. We developed a system of 784 ordinary
differential equations (see Table S7). We set the population size in
the model to 100,000 individuals, equally divided into females and
males. The epidemiologic model simulated heterosexual transmission of HPV-16/18 infections in males and females and
progression to CIN1 (cervical intraepithelial neoplasia stage 1),
CIN2/3 (cervical intraepithelial neoplasia stage 2/3) and cervical
cancer for females (see flow diagram on Figure 1). Description of
variables and parameters can be found in Appendix S1 (Table S4).
Fourteen-year-old persons entered the model at a genderspecific and sexual activity-specific rate. Sexually active men and
women could be infected with HPV 16/18 if they had had sexual
intercourse with infected individuals. Women with CIN1 or
wlo ~e No Co z(1{e)dlo
4
P
Ns Cs
s~1
Force of Infection
The force of infection by gender depends on: probabilities of
transmission by partnership (not per sex act) from an infected
Figure 1. Flow diagram in non-vaccinated population. For one age-group j (j = 114) and one group of sexual behavior l (l = 14): Black solid
arrows represent infection or progression of the disease; black dotted arrows represent clearance of infection or regression of the disease; gray
dotted arrows represent exit of the model (due to death or age .84); bold arrows represent specific mortality due to cervical cancer.
doi:10.1371/journal.pone.0032251.g001
Sensitivity analysis
Sensitivity analyses were conducted to assess the effect of
parameter variations on model results. The degree of sexual
mixing e, which can vary between 0 (fully assortative) and 1 (fully
random), was initially set to 0.4. We tested the effect of a value for
e closer to sexual mixing fully random (e = 0.8) on the endemic
prevalence of HPV infections in male and female. Although
vaccine efficacy was initially set to 90%, in sensitivity analyses, we
set vaccine efficacy to 60%. Thus, we studied the impact of
vaccination on HPV prevalence and cervical cancer incidence
using a low (60%) vaccine efficacy.
Vaccine characteristics
We divided the population into vaccinated and unvaccinated
categories. Individuals entered the model at 14 years old (being
vaccinated or not). Individuals in the youngest age groups ([1419]
and [2024]) could be vaccinated after entrance into the model in
accordance with the French vaccine program and then moved to
vaccinated categories. We considered several vaccination scenarios. Immunity from the vaccine was assumed to be sustained
lifelong and vaccine efficacy was assumed to be 90%. In the five
scenarios considered, vaccine coverage was assumed to be constant
in time. In the first scenario, coverage of vaccination (using 3 doses
of vaccines) was set to that observed in France in 2009 [9]: 30% of
women aged 1419 and 10% of women aged 2024 (Table 1). In
the second scenario, we added vaccination coverage in boys and
men with similar rates to the women in scenario 1. We thereafter
defined hypothetical high coverage in women only (80%) and both
genders in scenarios 3 and 4 respectively. Finally, in scenario 5,
young girls could be vaccinated before age of 14 with a highest
coverage than for girls aged 14 to 24 (50% versus 30%); in this
scenario, there was no vaccination in men.
Results
HPV infection prevalence
Tables 2 and 3 show predicted prevalence of HPV 16/18
infections in each considered scenario of vaccination coverage. All
vaccination strategies considered against HPV 16/18 led to a
sizeable decrease in prevalence in males and females 20 and 50
years after vaccination introduction (see Figure S4 and Figure S5).
There was a modest effect on the prevalence of HPV infections
when scenarios included vaccination coverage in men and women
compared to those considering vaccination coverage only in
females. For instance, in France, current vaccination coverage
among females lead to a 52% reduction of HPV infection
prevalence 20 years after the introduction of the vaccine, while
adding vaccination with a similar coverage in boys and young men
yielded a 59% reduction in HPV infection prevalence.
Improving vaccine coverage (scenario 3 and 4) decreased HPV
prevalence more importantly; in addition, the impact of the
vaccines was observed earlier in time.
Scenario 5, which considered an additional vaccination of girls
before 14, yielded a better impact on HPV prevalence among
Model validation
To validate the model, we considered the epidemiological data
before vaccination introduction and compared it with the steadystate estimates of the deterministic model for non-vaccinated
individuals (see Figure S3). Probabilities of transmission of HPV
16/18 (per partnership, from an infected individual to a
Table 1. Scenarios of vaccination considered in simulations.
Vaccine coverage
Scenario 1
Scenario 2
Scenario 3
Scenario 4
Women
Scenario 5
,14: 50%
[1419]
30%
30%
80%
80%
30%
[2024]
10%
10%
80%
80%
30%
[1419]
30%
80%
[2024]
10%
80%
Men
doi:10.1371/journal.pone.0032251.t001
Table 2. Prevalence of HPV 16/18 for women in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).
10 years
20 years
50 years
Without vaccination
20.2%
20.2%
20.2%
Scenario 1
14.4% (228.7%)
9.8% (251.7%)
2.6% (287.2%)
Scenario 2
13.7% (232.2%)
8.31% (258.9%)
0.85% (295.8%)
Scenario 3
11.0% (245.5%)
6.05% (270.0%)
0.6% (297.0%)
Scenario 4
10.1% (250%)
4.69% (276.8%)
0.09% (299.6%)
Scenario 5
12.2% (239.6%)
6.96% (265.6%)
0.9% (295.6%)
Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in HPV prevalence compared to the case without vaccination.
doi:10.1371/journal.pone.0032251.t002
Table 3. Prevalence of HPV 16/18 for men in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).
10 years
20 years
50 years
Without vaccination
19.4%
19.4%
19.4%
Scenario 1
15.1% (222.2%)
10.9% (243.8%)
3.7% (280.9%)
Scenario 2
13.1% (232.5%)
7.8% (259.8%)
0.8% (295.9%)
Scenario 3
12.2% (237.1%)
7.3% (262.4%)
1.1% (294.3%)
Scenario 4
9.6% (250.5%)
4.3% (277.8%)
0.1% (299.5%)
Scenario 5
13.3% (231.4%)
8.2% (257.7%)
1.5% (292.3%)
Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in HPV prevalence compared to the case without vaccination.
doi:10.1371/journal.pone.0032251.t003
Table 4. Incidence of cervical cancer due to HPV 16/18 in French women in each scenario 10, 20 and 50 years after initiation of
vaccination (t = 0).
10 years
20 years
50 years
100 years
Without vaccination
9.6
9.6
9.6
9.6
Scenario 1
8.9 (27.3%)
6.5 (232.3%)
1.6 (283%)
0.5 (294.8%)
Scenario 2
8.7 (29.4%)
6.0 (237.5%)
0.8 (291.7%)
0.02 (299.8%)
Scenario 3
8.1 (215.6%)
4.8 (250%)
0.5 (294.8%)
0.05 (299.5%)
Scenario 4
7.9 (217.7%)
4.2 (256.3%)
0.2 (297.9%)
,1025 (2100%)
Scenario 5
8.5 (211.5%)
5.3 (244.8%)
0.7 (292.7%)
0.07 (299.3%)
Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in cervical cancer incidence compared to the case without vaccination.
doi:10.1371/journal.pone.0032251.t004
Sensitivity analyses
In sensitivity analysis, we tested the impact of an increase of the
sexual mixing parameter that corresponded to an augmentation of
random mixing. A high value of the sexual mixing parameter
(e = 0.8) led to a 2% reduction of endemic prevalence of HPV
infections in males and females compared to the initial value of e
(0.4).
A lower efficacy of vaccine (60%) reduced the impact on HPV
prevalence and cervical cancer incidence. For instance, using
scenario 1, model predictions yielded 50 years after introduction of
vaccine a 25% higher HPV prevalence in females and a two-fold
increase of cervical cancer incidence compared to scenario 1 with
a 90% efficacy of vaccine.
Discussion
We developed a dynamical model for HPV transmission in a
heterosexual population to assess the impact of vaccination against
HPV infections on the incidence of cervical cancer in France. We
considered current vaccination policies and compared several
vaccination scenarios. We confirmed the effectiveness of vaccination against HPV to prevent infections and cervical cancers using
deterministic modeling [19,20,21,23]. However, the impact of
vaccination differed according to the various scenarios considered
in our paper. Vaccination coverage among young females under
14 and higher vaccination coverage in currently targeted females
(in France) improved the prevention of infections and cervical
cancers due to HPV 16/18 significantly.
The use of a deterministic model in our study allowed us to take
into account herd immunity, which corresponds to a decrease of
HPV 16/18 infections and cervical cancers in non-vaccinated
Table 5. Expected Diminution of number of deaths (per year)
due to cervical cancer after introduction of vaccine compared
to number of deaths without vaccine.
Scenario 1
25%
247%
288%
Scenario 2
26%
256%
297.5%
Scenario 3
28.84%
264%
297.2%
Scenario 4
210.58%
271%
299.4%
Scenario 5
27.16%
259%
296.17%
doi:10.1371/journal.pone.0032251.t005
Supporting Information
Appendix S1 Description of the mathematical model.
(DOC)
Figure S1 Distribution of women aged 14 to 84. Data
observed in France on 01/01/2006 in blue (www.insee.fr) versus
predicted by the demographic model in green.
(EPS)
Figure S2 Distribution of men aged 14 to 84. Data
observed in France on 01/01/2006 in blue (www.insee.fr) versus
predicted by the demographic model in green.
(EPS)
Figure S3 Number of new cases of cervical cancer due
to HPV 16/18 for 100,000 women per year. Published data
in blue [1], predicted by the model in green.
(EPS)
Figure S4 Female prevalence of HPV 16/18 infection
since introduction of vaccination (t = 0) in each scenario.
(TIF)
Figure S5 Male prevalence of HPV 16/18 infection since
introduction of vaccination (t = 0) in each scenario.
(TIF)
Figure S6 Evolution of cervical cancer incidence for
French women (number of new diagnosed cases annually per 100,000 women) after introduction of vaccination (t = 0).
(TIF)
Table S1 Initial distribution in the model in the 4
sexual-activity groups.
(DOC)
Table S2 Mixing matrix between age-group. Proportion
(DOC)
Table S4 Description of variables and parameters.
(DOC)
6
Acknowledgments
(DOC)
The authors would like to thank the referees for their comments, Bilal
Majed for his invaluable help and Carole Birkan-Berz for her assistance in
the preparation of the manuscript in English.
Author Contributions
tion.
(DOC)
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24. Garnett GP (2005) Role of herd immunity in determining the effect of vaccines
against sexually transmitted disease. J Infect Dis 191 Suppl 1: S97106.
25. Hethcote HW (1997) An age-structured model for pertussis transmission. Math
Biosci 145: 89136.
26. Bajos N, Bozon M, Beltzer N (2008) Enquete sur la sexualite en France :
pratiques, genre et sante. Paris: Decouverte. 609 p.
27. Garnett GP, Anderson RM (1993) Contact tracing and the estimation of sexual
mixing patterns: the epidemiology of gonococcal infections. Sex Transm Dis 20:
181191.
28. Nielson CM, Harris RB, Flores R, Abrahamsen M, Papenfuss MR, et al. (2009)
Multiple-type human papillomavirus infection in male anogenital sites:
prevalence and associated factors. Cancer Epidemiol Biomarkers Prev 18:
10771083.
29. Ralston Howe E, Li Z, McGlennen RC, Hellerstedt WL, Downs LS, Jr. (2009)
Type-specific prevalence and persistence of human papillomavirus in women in
the United States who are referred for typing as a component of cervical cancer
screening. Am J Obstet Gynecol 200: 245 e241247.
30. Duport N (2006) Donnees epidemiologiques sur le cancer du col de luterus/etat
des connaissances. Saint Maurice: InVS.
31. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006) Chapter 3: HPV
type-distribution in women with and without cervical neoplastic diseases.
Vaccine 24 Suppl 3: S3/2634.
32. Peto J, Gilham C, Deacon J, Taylor C, Evans C, et al. (2004) Cervical HPV
infection and neoplasia in a large population-based prospective study: the
Manchester cohort. Br J Cancer 91: 942953.
33. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, et al. (2008) Cancer
incidence and mortality in France over the period 19802005. Rev Epidemiol
Sante Publique 56: 159175.
34. Duport N (2008) Donnees epidemiologiques sur le cancer du col de luterus/etat
des connaissances. Saint Maurice: INVS.
35. Jin XW, Sikon A, Yen-Lieberman B (2011) Cervical cancer screening: Less
testing, smarter testing. Cleve Clin J Med 78: 737747.
36. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, et al. (2011)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6,
11, 16, 18) recombinant vaccine in adult women 2445 years of age. Br J Cancer
105: 2837.
37. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy
of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against
cervical infection and precancer caused by oncogenic HPV types (PATRICIA):
final analysis of a double-blind, randomised study in young women. Lancet 374:
301314.
38. Rambout L, Hopkins L, Hutton B, Fergusson D (2007) Prophylactic vaccination
against human papillomavirus infection and disease in women: a systematic
review of randomized controlled trials. CMAJ 177: 469479.
39. UK Department of Health website () HPV Vaccination Programme: Provisional
data, as submitted by PCTs, for First and Second dose vaccine uptake, for the
month ending 28 February 2010. Available: http://www.dh.gov.uk/prod
consum h/groups/dh digitalassets/documents/digitalasset/dh 115153.pdf. Accessed 2011 Aug 4.
40. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, et al.
(2008) Interim estimates of human papillomavirus vaccination coverage in the
school-based program in Australia. Commun Dis Intell 32: 457461.
41. Denis FL-BD (2006) Mass vaccination against hepatitis B: the French example.
Curr Top Microbiol Immunol 304: 115129.
42. ECCA European Cervical Cancer Association website () HPV vaccination
accross Europe. Available: http://www.ecca.info/fr/ecca-publications.html.
Accessed 2011 Jun 5.
43. Haut Conseil Sante Publique website () AVIS DU COMITE TECHNIQUE
DES VACCINATIONS et du CONSEIL SUPERIEUR DHYGIENE
PUBLIQUE DE FRANCE SECTION DES MALADIES TRANSMISSIBLES
Relatif a` la vaccination contre les papillomavirus humains 6, 11, 16 et 18
(seances du 9 mars 2007). Available: http://www.hcsp.fr/docspdf/cshpf/
a_mt_090307_papillomavirus.pdf. Accessed 2011 Dec 27.
44. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC (2011) Incremental
impact of adding boys to current human papillomavirus vaccination programs:
role of herd immunity. J Infect Dis 204: 372376.
45. Castle PE, Scarinci I (2009) Should HPV vaccine be given to men? BMJ 339:
b4127.
and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic
nonvaccine HPV types in generally HPV-naive women aged 1626 years.
J Infect Dis 199: 926935.
49. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/
18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate
cross-protection. Vaccine 29: 20112014.
46. Elbasha EH, Dasbach EJ (2010) Impact of vaccinating boys and men against
HPV in the United States. Vaccine 28: 68586867.
47. Foresta C, Ferlin A, Garolla A (2009) HPV vaccination. What about male
specific HPV related diseases? BMJ 339: b4514.
48. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al.
(2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16,